News
Novavax stock was climbing again on Monday after the company expressed new confidence in the eventual approval of its ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
Analysis found 25% tariff on pharmaceutical imports would hike U.S. drug costs by nearly $51 billion annually, boosting ...
13h
Stocktwits on MSNNovavax Tops Weekly Retail Buzz Spike Amid FDA Trial Drama, COVID-19 Vaccine Approval HopesNovavax, Inc. (NVAX) shares jumped nearly 12.6% over the past week, leading to a surge in retail investor chatter following ...
A summary of current health news, including the disbanding of a U.S. Justice Department unit focusing on food and drug safety ...
After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.
Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological E. Clinical trials are underway, and the company aims to ...
Markets were also boosted by the prospect of a quieter geopolitical environment, as the US attempts to smooth the wrinkles in ...
Brinker, the owner of Chili's, has seen shares soar 20% so far in 2025. The earnings report on Tuesday could take them a leg up or down. The additional step, which could cost millions of dollars, goes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results